{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:34:40Z","timestamp":1777419280324,"version":"3.51.4"},"reference-count":26,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2005,5]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To report the probable association of angioedema with aspirin therapy and the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CASE SUMMARY:<\/jats:title>\n                    <jats:p>A 44-year-old white woman, previously tolerant to aspirin and other nonsteroidal antiinflammatory drugs (NSAIDs), developed angioedema of the lips after ingesting two 325-mg aspirin tablets during one day. The reaction occurred 3 hours after taking the second aspirin and resolved within 3 hours. Two weeks later, the patient took a 25-mg rofecoxib tablet for a sore throat, and she developed angioedema 51\/2 hours later. Although the woman took 50 mg of diphenhydramine, the swelling did not subside. She repeated the diphenhydramine dose in the evening and, by noon the next day, 261\/2 hours after the angioedema began, it was resolved. The patient's internist prescribed an epinephrine auto-injector and advised her to consult an allergist. With skin testing and oral rechallenge with aspirin, but not rofecoxib, the allergist determined the cause of the reactions to be aspirin-induced angioedema and selective COX-2 inhibitor intolerance. The Naranjo probability scale indicated that aspirin was a highly probable cause and rofecoxib was a probable cause of this patient's angioedema.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION:<\/jats:title>\n                    <jats:p>Aspirin-induced angioedema and NSAID intolerance have been well documented. There are reports of both tolerance and intolerance to selective COX-2 inhibitors in patients with documented allergy-like reactions to aspirin and NSAIDs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Patients with aspirin and NSAID intolerance may develop intolerance to COX-2 inhibitors, especially with repeated exposure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1e546","type":"journal-article","created":{"date-parts":[[2005,4,6]],"date-time":"2005-04-06T09:32:41Z","timestamp":1112779961000},"page":"944-948","source":"Crossref","is-referenced-by-count":7,"title":["Angioedema Associated with Aspirin and Rofecoxib"],"prefix":"10.1177","volume":"39","author":[{"given":"Leisa L","family":"Marshall","sequence":"first","affiliation":[{"name":"Leisa L Marshall PharmD CGP FASCP, Clinical Associate Professor, Department of Clinical and Administrative Sciences, Mercer University Southern School of Pharmacy, 3001 Mercer University Dr., Atlanta, GA 30341-4155, fax 678\/547-6384"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2005,5,1]]},"reference":[{"key":"bibr1-aph.1E546","first-page":"745","volume":"21","author":"Stevenson DD","year":"2001","journal-title":"Immunol Allergy Clin North Am"},{"key":"bibr2-aph.1E546","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr3-aph.1E546","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.121315"},{"key":"bibr4-aph.1E546","doi-asserted-by":"publisher","DOI":"10.1385\/CRIAI:24:2:125"},{"key":"bibr5-aph.1E546","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2004.03.001"},{"key":"bibr6-aph.1E546","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62226-0"},{"key":"bibr7-aph.1E546","unstructured":"Martinez B, Mathews AW, Lublin JS, Winslow R. Merck pulls Vioxx from market after link to heart problems. Wall Street Journal 2004 (Oct 1):A1, A12."},{"key":"bibr8-aph.1E546","volume-title":"Bextra (valdecoxib)","author":"Package insert","year":"2004"},{"key":"bibr9-aph.1E546","volume-title":"Package insert. Celebrex (celecoxib)","year":"2004"},{"key":"bibr10-aph.1E546","volume-title":"Package insert. Vioxx (rofecoxib)","year":"2004"},{"key":"bibr11-aph.1E546","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2001.056008789.x"},{"key":"bibr12-aph.1E546","first-page":"47","volume":"108","author":"Stevenson DD","year":"2001","journal-title":"Clin Immunol"},{"key":"bibr13-aph.1E546","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)61912-6"},{"key":"bibr14-aph.1E546","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.2001.01075.x"},{"key":"bibr15-aph.1E546","doi-asserted-by":"publisher","DOI":"10.1378\/chest.121.6.1812"},{"key":"bibr16-aph.1E546","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2000.110926"},{"key":"bibr17-aph.1E546","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(02)81546-9"},{"key":"bibr18-aph.1E546","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.12.1577"},{"key":"bibr19-aph.1E546","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-200194020-00019"},{"key":"bibr20-aph.1E546","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62017-0"},{"key":"bibr21-aph.1E546","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(03)80570-5"},{"key":"bibr22-aph.1E546","doi-asserted-by":"publisher","DOI":"10.1159\/000073268"},{"key":"bibr23-aph.1E546","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2001.00300.x"},{"key":"bibr24-aph.1E546","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200112203452518"},{"key":"bibr25-aph.1E546","first-page":"2553","volume":"28","author":"Kelkar PS","year":"2001","journal-title":"J Rheumatol"},{"key":"bibr26-aph.1E546","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2002.1n3581.x"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1E546","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1E546","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1E546","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:10:12Z","timestamp":1777374612000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1E546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["10.1345\/aph.1E546"],"URL":"https:\/\/doi.org\/10.1345\/aph.1e546","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}